Short answer: Splitting the same weekly amount into two shots gives smaller peaks and higher troughs, because cypionate and enanthate have half-lives of about a week.12 US labels only list every 2 to 4 weeks; the Endocrine Society gives weekly or every-2-week examples.3 No randomized trial has compared weekly with twice-weekly injections. Schedule changes go through your prescriber.
| Once weekly | Twice weekly (same weekly total) | |
|---|---|---|
| Where it comes from | Endocrine Society guideline example: 75 to 100 mg weekly3 | Not in the labels or the guideline; a split of the weekly amount |
| Label dosing schedule | Labels list 50 to 400 mg every 2 to 4 weeks14 | Same labels; neither lists twice weekly |
| Half-life of the ester | Cypionate about 8 days1; enanthate about 7.2 days in one study2 | Same esters |
| Peaks and troughs | Larger swing between peak and trough | Smaller swing: each shot is half the size and the gap is half as long |
| Evidence on frequency | Snyder 1980: 100 mg enanthate weekly gave higher mean levels than 200 mg every 2 weeks or longer intervals5 | No randomized trial against weekly |
| Hematocrit | Injections overall linked to more hematocrit above 50% than gels or pellets6 | No trial shows twice weekly lowers hematocrit; not established |
| Shots per month | About 4 | About 8 |
| Blood test timing | Guideline: midway between injections3 | Midway between injections |
| Notable warnings (both) | Raised hematocrit, blood pressure increases, BPH, VTE1 | Same |
With a half-life of about a week, roughly half of what was released is still there a week later. Inject the whole weekly amount at once and levels rise to a higher peak and fall further before the next shot. Split it in two and each peak is smaller and each trough comes sooner, so levels swing less. The average over the week stays about the same, because the total amount does.
This is pharmacokinetic reasoning, not a trial result. The older Snyder study compared intervals of 1 to 4 weeks with enanthate and found the weekly 100 mg schedule gave the highest average levels.5
It is often claimed, but not shown in a randomized trial. What is documented is that injections as a group are associated with more raised hematocrit than gels or pellets: in one clinic study, 66.7% of men on injections had hematocrit above 50%, vs 12.8% on gels and 35.1% on pellets.6 The guideline advises checking hematocrit at baseline, at 3 to 6 months and yearly, and stopping if it goes above 54%.3
The Endocrine Society guideline suggests measuring testosterone midway between injections and adjusting if it is above 600 or below 350 ng/dL.3 On a twice-weekly schedule, midway is about a day and a half after a shot, so the exact injection time matters.